Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium
Liquidia Corporation (NASDAQ: LQDA) has announced its participation in the Pulmonary Hypertension Professional Association (PHPN) Symposium from September 18-20, 2025, in Seattle. The company will present four posters, including new safety and efficacy data from their ASCENT study of YUTREPIA™ (LIQ861) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The presentations will take place on September 19, 2025, from 3:45-4:30 PM PT, featuring one live thematic poster and three encore presentations. The posters will cover YUTREPIA's impact on cardiac effort, quality of life, patient device usage, and Week 8 safety data from the ASCENT study.
Liquidia Corporation (NASDAQ: LQDA) parteciperà al Simposio della Pulmonary Hypertension Professional Association (PHPN), in programma dal 18 al 20 settembre 2025 a Seattle. L'azienda presenterà quattro poster, comprensivi di nuovi dati di sicurezza ed efficacia dello studio ASCENT su YUTREPIA™ (LIQ861) in pazienti con ipertensione polmonare associata a malattia polmonare interstiziale (PH-ILD).
Le presentazioni si terranno il 19 settembre 2025 dalle 15:45 alle 16:30 PT e includeranno un poster tematico in sessione live e tre presentazioni in replica. I poster tratteranno l'impatto di YUTREPIA sul lavoro cardiaco, sulla qualità della vita, sull'utilizzo del dispositivo da parte dei pazienti e i dati di sicurezza della settimana 8 dello studio ASCENT.
Liquidia Corporation (NASDAQ: LQDA) ha anunciado su participación en el Simposio de la Pulmonary Hypertension Professional Association (PHPN), que se celebrará del 18 al 20 de septiembre de 2025 en Seattle. La compañía presentará cuatro pósteres, incluidos nuevos datos de seguridad y eficacia del estudio ASCENT sobre YUTREPIA™ (LIQ861) en pacientes con hipertensión pulmonar asociada a enfermedad pulmonar intersticial (PH-ILD).
Las presentaciones tendrán lugar el 19 de septiembre de 2025 de 3:45 a 4:30 PM PT, con un póster temático en sesión en vivo y tres presentaciones en repetición. Los pósteres abordarán el impacto de YUTREPIA en el esfuerzo cardíaco, la calidad de vida, el uso del dispositivo por parte de los pacientes y los datos de seguridad a la semana 8 del estudio ASCENT.
Liquidia Corporation (NASDAQ: LQDA)는 2025년 9월 18일부터 20일까지 시애틀에서 열리는 Pulmonary Hypertension Professional Association (PHPN) 심포지엄에 참여한다고 발표했습니다. 회사는 간질성 폐질환 관련 폐고혈압(PH-ILD) 환자를 대상으로 한 ASCENT 연구의 YUTREPIA™ (LIQ861)에 관한 새로운 안전성 및 유효성 데이터를 포함해 네 편의 포스터를 발표할 예정입니다.
발표는 2025년 9월 19일 태평양 시간 오후 3시45분부터 4시30분까지 진행되며, 라이브 주제 포스터 한 편과 재상영 세 편을 포함합니다. 포스터들은 YUTREPIA가 심장 부담, 삶의 질, 환자의 기기 사용 및 ASCENT 연구의 8주차 안전성 데이터에 미치는 영향을 다룹니다.
Liquidia Corporation (NASDAQ: LQDA) a annoncé sa participation au symposium de la Pulmonary Hypertension Professional Association (PHPN), qui se tiendra du 18 au 20 septembre 2025 à Seattle. La société présentera quatre affiches, incluant de nouvelles données de sécurité et d'efficacité issues de l'étude ASCENT sur YUTREPIA™ (LIQ861) chez des patients atteints d'hypertension pulmonaire associée à une maladie pulmonaire interstitielle (PH-ILD).
Les présentations auront lieu le 19 septembre 2025 de 15h45 à 16h30 PT et comprendront une affiche thématique en session en direct et trois présentations en rediffusion. Les affiches porteront sur l'impact de YUTREPIA sur l'effort cardiaque, la qualité de vie, l'utilisation du dispositif par les patients et les données de sécurité à la semaine 8 de l'étude ASCENT.
Liquidia Corporation (NASDAQ: LQDA) hat seine Teilnahme am Pulmonary Hypertension Professional Association (PHPN) Symposium angekündigt, das vom 18. bis 20. September 2025 in Seattle stattfindet. Das Unternehmen wird vier Poster vorstellen, darunter neue Sicherheits- und Wirksamkeitsdaten aus der ASCENT-Studie zu YUTREPIA™ (LIQ861) bei Patientinnen und Patienten mit pulmonaler Hypertonie im Zusammenhang mit interstitieller Lungenerkrankung (PH-ILD).
Die Präsentationen finden am 19. September 2025 von 15:45 bis 16:30 Uhr PT statt und umfassen ein thematisches Live-Poster sowie drei Wiederholungspräsentationen. Die Poster behandeln YUTREPIAs Auswirkungen auf die kardiale Belastung, die Lebensqualität, die Nutzung des Geräts durch Patientinnen und Patienten sowie Sicherheitsdaten aus Woche 8 der ASCENT-Studie.
- None.
- None.
MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium taking place September 18 – 20, 2025, in Seattle.
In a live thematic poster session, Liquidia will highlight new safety and exploratory efficacy data pertaining to patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) who have participated in its fully enrolled ASCENT study of LIQ861 (YUTREPIA™) through Week 8. Liquidia will also present three previously published posters that highlight YUTREPIA’s impact on cardiac effort, its impact on quality of life and patient use of the device.
All posters will be presented on Friday, September 19, 2025 from 3:45 – 4:30 p.m. PT. Upon presentation, each poster will be available on the Publications page of Liquidia’s website at https://liquidia.com/publications.
Live Thematic Poster Session
Poster Discussion Session: Poster Board #1037
Abstract: A Continued ASCENT to Week 8: Initial Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients
Encore Thematic Poster Sessions
Poster Discussion Session: Poster Board #1041
Abstract: Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from the ASCENT Trial
Poster Discussion Session: Poster Board #1051
Abstract: Quality of Life (QOL) in PAH Patients Receiving an Inhaled Dry Powder Treprostinil (LIQ861) in the INSPIRE Study
Poster Discussion Session: Poster Board #1053
Abstract: Robustness of LIQ861, a Dry-Powder Inhaled Formulation of Treprostinil, in Patient Misuse Scenarios
About YUTREPIA™ (treprostinil) Inhalation Powder
YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (NASDAQ: LQDA) present at the PHPN Symposium 2025?
What data will Liquidia present about YUTREPIA at the PHPN Symposium?
Where can investors access Liquidia's PHPN Symposium 2025 poster presentations?
What is the focus of Liquidia's ASCENT study being presented at PHPN?
